The IMID Forum

Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy. In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre and Doctor Frank Behrens, Medical director at Goethe-University, as they discuss two interesting areas of the modern PsA therapeutic landscape. The first of the publications discussed pertains to the use of secukinumab in oligoarticular PsA. We will then go on to expand upon the latest in the evolving story begun by ORAL Surveillance, as we discuss the latest meta-analysis of the relationship between JAK inhibition and malignancies.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Laura Coates a NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing her recent paper 'Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study'.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.

Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.

Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.

Join Professor Peter Nash as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2023 today (Saturday 3 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Professor Lorenzo Dagna as she goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2023 today (Friday 2 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Dr Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2023 today (Thursday 1st June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients. In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate. In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.

Join Professor Xavier Mariette as he goes through our top abstracts, posters, and presentations from Day 1 of EULAR 2023 today (Wednesday 31 May). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Professor Peter Nash as he previews our highlights this EULAR, introducing some of the top abstracts we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.

Join Professors Peter Nash, Laura Coates, and Frank Behrens as they discuss the latest top research in PsA. The papers covered in this topical discussion highlight two fascinating therapeutics used in PsA treatment. This includes the latest evaluation of the efficacy and safety of guselkumab in DISCOVER-1 patients with active PsA by prior use of TNFi, as well as the latest investigation into the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.

Dr Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin where she is also Medical Director of the psoriatic arthritis program. In this edition, Dr Singla discusses ehr latest paper 'Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.'

Join Dr. Sofia Ramiro and Professor Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses the incidence of MACEs in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Our second paper the goes on to evaluate the long-term safety profile for upadacitinib across RA, PsA, AS and AD.

Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs. In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs. In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi. To access detailed summary slides of the papers discussed today, visit cytokinesignalling.com.

Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Join Prof Iain McInnes as he reviews two interesting papers. In the first of today’s papers, Jeffrey Curtis and colleagues aimed to evaluate malignancies and their associations with baseline risk factors and CV risk scores with tofacitinib vs TNFi in a CV risk-enriched RA population from the ORAL Surveillance study. In the second paper today, Peter Taylor and his team analyse data from the baricitinib clinical trial programme for rheumatoid arthritis, atopic dermatitis, and alopecia areata, to help further characterise adverse events of special interest for JAK inhibitors in ‘at-risk’ populations.

Dr. Charis Meng, a rheumatologist at the Hospital for Special Surgery and Assistant Professor at Weill Cornell Medical College in New York. In this edition, Dr Meng discusses her latest paper ‘Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis.’

Join Prof Iain McInnes as he reviews two interesting papers. In the first paper, Professor Maxime Dougados and colleagues shed some more light into the findings from the ORAL Surveillance trial, in comparison to those seen in the tofacitinib clinical development programme. And, in the second paper, Professor Kevin Winthrop and colleagues continue to report on safety by providing us with the latest findings from their review into opportunistic infections associated with JAK inhibitor treatment for RA.

Join Professors Atul Deodhar, Hideto Kameda, Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses new and emerging treatments for SpA. In particular it shines a light on treatments within axSpA. Following this, our second paper sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Join Prof Iain McInnes as he reviews two interesting papers. In the first paper the authors cover aspects from mean disease activity scores after tapering to radiographic outcomes and safety, to help ascertain whether it is possible to withdraw MTX while maintaining disease control. The second paper then goes on to also analyse MTX withdrawal data, but this time to evaluate the performance of disease activity metrics. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com

Professor Kevin Winthrop, Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, from Oregon Health and Science University, USA, as well as a CSF Steering Committee member. In this edition Professor Winthrop discusses his recent paper 'Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.'

Join Professor Philip Mease and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in December 2022. The first of our papers discusses the latest trial of a novel scoring system for inflammation and tissue damage, whilst the second paper compares adjunctive therapy usage in patients treated with IL-17A inhibitors.

Dr Rebecca Haberman from the Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, USA. In this edition Dr Haberman disucsses her recent paper ‘Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.’

Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'

Dr Claudia Salinas, Director Pharmacoepidemiology at Eli Lilly and Company, Indianapolis, USA. In this addition Dr Salinas discusses her recent paper 'Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease registries and Claims Databases.'

Join Prof Iain McInnes as he reviews two interesting papers. The first highlights one of the three systematic literature reviews carried out to inform the 2022 EULAR RA management recommendations task force with the available evidence published since 2019. The second paper in today’s podcast looks at the recommendations themselves, by Smolen, et al, and I’ll highlight what’s remained the same and what’s changed from the 2019 recommendations. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professor Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications details the 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. The second of today’s papers explores the efficacy and safety of bDMARDs in axSpA managment. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs versus those with fewer than four PPFs. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Discussing Rheumatology: October 2022 by The Immune-Mediated Inflammatory Disease Forum

Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of COMBIO, or Combination of Targeted Therapies, in clinical settings. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'

Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial. Finally, our third paper reports the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.

Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration.

Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers from May and June. The first -by Faquetti , et al.- provides some insightful information into the pharmacological effects of tofacitinib and baricitinib. Our second paper then goes on to evaluate the real-life effectiveness and safety outcomes of four current second-line therapies of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professors McInnes and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients with active PsA. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Author Interview: Diego Kyburz by The Immune-Mediated Inflammatory Disease Forum

Discussing Rheumatology: June 2022 by The Immune-Mediated Inflammatory Disease Forum

Discussing axSpA: Episode 1 by The Immune-Mediated Inflammatory Disease Forum

Join Dr Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus adalimumab in patients with active PsA and IR to biologic/non-biologic DMARDs. And finally, our speakers discuss new data from Merola et al on the effect of secukinumab CV risk factors and inflammatory biomarkers. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Douglas Veale takes you through our top picks from the selection of abstracts presented at the final day of EULAR 2022 (Saturday 4 June). Today's podcast covers RA, PsA, and axSpA.

Douglas Veale takes you through our top picks from the selection of abstracts at EULAR 2022 today (Friday 3 June). Today's podcast covers RA, PsA, and axSpA.

Laura Coates takes you through our top picks from the selection of abstracts at EULAR 2022 today (Thursday 2 June). Today's podcast covers RA, PsA, and axSpA.

Laura Coates takes you through our top picks from the selection of rheumatoid arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!